Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Equivalents (2018 - 2026)

Revolution Medicines has reported Cash & Equivalents over the past 8 years, most recently at $383.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 29.34% year-over-year to $383.7 million; the TTM value through Dec 2025 reached $383.7 million, down 29.34%, while the annual FY2025 figure was $383.7 million, 29.34% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $383.7 million at Revolution Medicines, up from $217.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $696.1 million in Q4 2023 and troughed at $97.7 million in Q1 2022.
  • A 5-year average of $291.8 million and a median of $282.1 million in 2024 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 715.82% in 2021 and later plummeted 72.22% in 2022.
  • Year by year, Cash & Equivalents stood at $108.5 million in 2021, then surged by 48.77% to $161.4 million in 2022, then surged by 331.29% to $696.1 million in 2023, then fell by 21.99% to $543.1 million in 2024, then fell by 29.34% to $383.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for RVMD at $383.7 million in Q4 2025, $217.4 million in Q3 2025, and $402.4 million in Q2 2025.